Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | AKT2 | P31751 | 2/20 | 0.43 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27385330 | 1.00 | PIK3CA (0.44) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL27385304 | 0.90 | PIK3CA (0.55) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30857957 | 0.90 | PIK3CA (0.55) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL27385323 | 0.89 | PIK3CA (0.43) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30857948 | 0.87 | PIK3CA (0.47) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30857911 | 0.85 | AKT1 (0.46) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30858045 | 0.81 | PIK3CA (0.47) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30857909 | 0.75 | AKT1 (0.56) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL27385159 | 0.75 | AKT1 (0.56) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30783637 | 0.74 | AKT1 (0.66) | PIK3CAAKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602031-A1 | METHODS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024081904-A1 | METHODS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |